SPTX (Seaport Therapeutics) 12-1 Month Momentum %: N/A% (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SPTX Seaport Therapeutics Inc SPTX
11 GF Score
Price $24.04
! 2 Warning Signs
View Full Analysis

What is Seaport Therapeutics 12-1 Month Momentum %?

Seaport Therapeutics SPTX -0.99% 11 12-1 Month Momentum % is N/A% as of Aug. 19, 2026. GuruFocus rates SPTX with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,359 Biotechnology companies, Seaport Therapeutics ranks worse than 73583.44% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-19), Seaport Therapeutics's 12-1 Month Momentum % is N/A%.

The industry rank for Seaport Therapeutics's 12-1 Month Momentum % or its related term are showing as below:

SPTX's 12-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -19.95
* Ranked among companies with meaningful 12-1 Month Momentum % only.

Seaport Therapeutics  (NAS:SPTX) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Seaport Therapeutics 12-1 Month Momentum % Related Terms

SPTX
11GF Score
Seaport Therapeutics Inc SPTX
12-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seaport Therapeutics  (NAS:SPTX) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of N/A% mean?
Seaport Therapeutics (SPTX) has a 12-1 Month Momentum % of N/A% as of Aug. 19, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Seaport Therapeutics and its competitors. According to the industry distribution chart, Seaport Therapeutics ranks #999999 out of 1359 companies in the Biotechnology industry.
Is Seaport Therapeutics' 12-1 Month Momentum % too high?
Seaport Therapeutics' current 12-1 Month Momentum % is N/A%. Based on the distribution chart, Seaport Therapeutics ranks #999999 out of 1359 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Seaport Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Seaport Therapeutics' 12-1 Month Momentum % compare to SVRA and DRTS?
According to the Biotechnology industry distribution chart, Seaport Therapeutics ranks #999999 out of 1359 companies for 12-1 Month Momentum %. This places Seaport Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Seaport Therapeutics and its competitors. Seaport Therapeutics's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seaport Therapeutics stock overvalued right now?
Seaport Therapeutics (SPTX) has a current 12-1 Month Momentum % of N/A%. The current 12-1 Month Momentum % is N/A%. Seaport Therapeutics' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Seaport Therapeutics (SPTX), the current 12-1 Month Momentum % is N/A% as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seaport Therapeutics Business Description

Address 101 Seaport Boulevard, Floor 12, Boston, MA, USA, 02210
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
11GF Score

Get the complete analysis for SPTX

12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.04
Price